These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39083396)

  • 21. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study.
    Kim JH
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.
    Takeda T; Sugimoto S; Matsumoto J; Iwata N; Nakamoto A; Ozaki AF; Hamano H; Ariyoshi N; Zamami Y
    Int J Clin Pharm; 2024 Apr; 46(2):536-541. PubMed ID: 38240964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
    Zhu J; Hu M; Liang Y; Zhong M; Chen Z; Wang Z; Yang Y; Luo Z; Zeng W; Li J; Du Y; Liu Y; Yang C
    Heliyon; 2024 Jul; 10(14):e34837. PubMed ID: 39149028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system.
    Fang Z; Xu Z; Zhu W; Yu M; Ji C
    Front Pharmacol; 2023; 14():1101861. PubMed ID: 37342589
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.
    Chen X; Jiang Y; Zhu H; Tian M
    Front Pharmacol; 2024; 15():1417661. PubMed ID: 39380910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
    Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
    J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system.
    Jin Y; Fan M; Zheng X; Zhu S
    Expert Opin Drug Saf; 2024 Aug; ():1-6. PubMed ID: 39167069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 39. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS.
    Dai M; Dou X; Chen M; Yang J; Long J; Lin Y
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4105-4121. PubMed ID: 38032491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.